View
0
Download
0
Category
Preview:
Citation preview
348
CHAPTER-4
349
4. BIBLIOGRAPHY
1. Roth B. Design of dihydrofolate reductase inhibitors from X-ray crystal
structures. Fed Proc 1986; 45: 2765-2772.
2. Falco EA, Hitchings GH, Russell PB, Vanderwerff H. Antimalarials as
antagonists of purines and pteroylglutamic acid. Nature 1949; 164: 107.
3. Burchall JJ, Hitchings GH. Inhibitor binding analysis of dihydrofolate
reductases from various species. Mol Pharmacol 1965; 1: 126-136.
4. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The
pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:
1094-1104.
5. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR.
Methotrexate induces clinical and histologic remission in patients with
refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356.
6. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et
al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med
1985; 312: 818-822.
7. Weinstein GD, Frost P. Methotrexate for psoriasis: a new therapeutic
schedule. Arch Dermatol 1971; 103: 33-38.
8. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT.
Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological
outcome. J Rheumatol 1995; 22: 241-245.
9. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel
CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A
double-blind crossover study. N Engl J Med 1988; 318: 603-607.
350
10. Green E, Demos CH. In folate antagonists as therapeutic agents. Sirotnak FM,
Burchall JJ, Ensminger WD, Montgomery JA, editors. Academic Press:
Orlando. 1984; 2: 192-249.
11. Ferone R, Burchall JJ, Hitchings GH. Plasmodium berghei dihydrofolate
reductase isolation, properties, and inhibition by antifolates. Mol Pharmacol
1969; 5: 49-59.
12. Kan SC, Siddiqui WA. Comparative studies on dihydrofolate reductases from
Plasmodium falciparum and Aotus trivirgatus. J Protozool 1979; 26: 660-664.
13. Maroun J. Clinical response to trimetrexate as sole therapy for non-small cell
lung cancer. Semin Oncol 1988; 15: 17-21.
14. Allegra CJ, Chabner BA, Tuazon CU, Arakaki DO, Baird B, Drake JC et al.
Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients
with the acquired immunodeficiency syndrome. N Engl J Med 1987; 317:
978-985.
15. Blaney JM, Hansch C, Silipo C, Vittoria A. Structure-activity relationships of
dihydrofolated reductase inhibitors, structure-activity relationships of
dihydrofolated reductase inhibitors. Chem Rev 1984; 84: 333-407.
16. Kisliuk RL. Folate biochemistry in relation to antifolate selectivity. In
antifolate drugs in cancer therapy. Jackman AL, editor. Humana Press,
Totowa, NJ. 1999; 13-36.
17. Thien KR, Blair JA, Leeming RJ, Cooke WT, Melikian V. Serum folates in
man. J Clin Pathol 1977; 30: 438-448.
18. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA et al. In
cancer chemotherapy and biological response modifiers; Pinedo HM, Longo
DL, Chabner BA, editors. New York: Elsevier Science; 1999; 1-38.
351
19. Barredo J, Moran RG. Determinants of antifolate cytotoxicity:
folylpolyglutamate synthetase activity during cellular proliferation and
development. Mol Pharmacol 1992; 42: 687-694.
20. Johnson TB, Nair MG, Galivan J. Role of folylpolyglutamate synthetase in the
regulation of methotrexate polyglutamate formation in H35 hepatoma cells.
Cancer Res 1988; 48: 2426-2431.
21. Allegra CJ. Antifolates. In cancer chemotherapy: Principles and practice.
Chabner B, Collins J, editors. Philadelphia: Lippincott ; 1990; 110-153.
22. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its
polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981; 41:
2751-2756.
23. Coward JK, Parameswaran KN, Cashmore AR, Bertino JR. 7,8-
Dihydropteroyl oligo-γ-L-glutamates. Synthesis and kinetic studies with
purified dihydrofolate reductase from mammalian sources. Biochemistry
1974; 13: 3899-3903.
24. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG. Inhibition of
human dihydrofolate reductase by antifolyl polyglutamates. Biochem
Pharmacol 1989; 38: 541-543.
25. Kisliuk RL, Gaumont Y, Baugh CM, Galivan J, Maley GF, Maley F. In
chemistry and biology of pteridines. Kisliuk RL, Brown GM, editors. North-
Holland: New York. Elsevier. 1979; 261.
26. Allegra CJ, Chabner BA, Tuazon CU, Arakaki OD, Baird B, Drake JC et al.
Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired
immunodeficiency syndrome (AIDS). Semin Oncol 1988; 15: 46-49.
352
27. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of
phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate
and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82:
4881-4885.
28. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-
carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate
deaminase by polyglutamates of methotrexate and oxidized folates and by 5-
aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236:
193-200.
29. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of
methotrexate. Increased adenosine release at inflamed sites diminishes
leukocyte accumulation in an in vivo model of inflammation. J Clin Invest
1993; 92: 2675-2682.
30. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal
adenosine in inflammatory bowel disease: Effect of methotrexate. Inflamm
Bowel Dis 1999; 5: 167-173.
31. Urakawa K, Mihara M, Suzuki T, Kawamura A, Akamatsu K, Takeda Y,
Kamatani N. Polyglutamation of antifolates is not required for induction of
extracellular release of adenosine or expression of their anti-inflammatory
effects. Immunopharmacology 2000; 48: 137-144.
32. Seeger DR, Cosulich DB, Smith JM, Hultquist ME. Analogs of
pteroylglutamic acid. III. 4-Amino derivatives. J Am Chem Soc 1949; 71:
1753-1758.
353
33. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP.
Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion
of activated peripheral T cells. J Clin Invest 1998; 102: 322-328.
34. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms
of action of methotrexate. Immunopharmacology 2000; 47: 247-257.
35. Bertino JR, Mini E, Sobrero A, Moroson BA, Love T, Jastreboff M et al.
Advances in Enzyme Regulation. 24; Weber G. editor. New York: Pergamon;
1985; 3-11.
36. Bertino JR, Srimatkandada S, Carman MD, Mini E, Jastreboff M, Moroson
BA et al. Mechanism of drug resistance in human leukemia. Haematol Blood
Transfus 1985; 29: 90-95.
37. Elslager EF, Davoll J: Synthesis of fused pyrimidines as folate antagonists. In:
Castle RN, Townsend LR, editors. Lectures in Heterocyclic Chemistry, vol 2.
Orem, Utah, Hetero, 1974; S97–S133.
38. Elslager EF, Johnson JL, Werbel LM. Folate antagonists. 20. Synthesis and
antitumor and antimalarial properties of trimetrexate and related 6-
[(phenylamino)methyl]-2,4-quinazolinediamines. J Med Chem 1983; 26:
1753-1760.
39. Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EF. 2,4-
Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a
potent non-classical folate antagonist inhibitor-I: Effect of dihydrofolate
reductase and growth of rodent tumors in vitro and in vivo. Biochem
Pharmacol 1979; 28: 1983-1987.
40. Weir EC, Cashmore AR, Dreyer RN, Graham ML, Hsiao N, Moroson BA et
al. Pharmacology and toxicity of a potent ”nonclassical” 2,4-diamino
354
quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982;
42: 1696-1702.
41. Lin JT, Cashmore AR, Baker M, Dreyer RN, Ernstoff M, Marsh JC et al.
Phase I studies with trimetrexate: clinical pharmacology, analytical
methodology, and pharmacokinetics. Cancer Res 1987; 47: 609-616.
42. Landis NT. Initial triservice formulary ready for use. Pharmacoeconomic
center will issue quarterly updates. Am J Hosp Pharm 1994; 51: 591.
43. Grivsky EM, Lee S, Sigel CW, Duch DS, Nichol CA. Synthesis and antitumor
activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]
pyrimidine. J Med Chem 1980; 23: 327-329.
44. Duch DS, Edelstein MP, Bowers SW, Nichol CA. Biochemical and
chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxylbenzyl)-5-
methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of
dihydrofolate reductase. Cancer Res 1982; 42: 3987-3994.
45. Kovacs JA, Allegra CJ, Swan JC, Drake JC, Parrillo JE, Chabner BA et al.
Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-
soluble antifolate. Antimicrob Agents Chemother 1988; 32: 430-433.
46. Perkins W, Williams REA, Vestey JP, Tidman MJ, Layton AM, Cunliffe WJ
et al. A multicentre 12-week open study of a lipid-soluble folate antagonist,
piritrexim in severe psoriasis. Br J Dermatol 1993; 129: 584-589.
47. Guzzo C, Benik K, Lazarus G, Johnson J, Weinstein G. Treatment of psoriasis
with piritrexim, a lipid-soluble folate antagonist. Arch Dermatol 1991; 127:
511-514.
355
48. Cramer SM, Schornagel JH, Kalghatgi KK, Bertino JR, Horvath C.
Occurrence and significance of D-methotrexate as a contaminant of
commercial methotrexate. Cancer Res 1984; 44: 1843-1846.
49. Gready JE. Advances in Pharmacology and Chemotherapy. New York,
Academic Press. 1980; 17: 37-102.
50. McCormack JJ. Dihydrofolate reductase inhibitors as potential drugs. Med
Res Rev 1981; 1: 303-331.
51. Rosowsky A. Chemistry and biological activity of antifolates. Prog Med
Chem 1989; 26: 1-252.
52. Baker BR. Design of Active-Site-Directed Irreversible Enzyme Inhibitors.
New York, Wiley. 1967; 199.
53. Montgomery JA, Piper JR. Folate Antagonists as Therapeutic Agents;
Sirotnak FM, Burchall JJ, Ensminger WB, Montgomery JA, editors. Orlando,
Academic Press: 1984; 219-260.
54. Piper JR, McCaleb GS, Montgomery JA, Kisliuk RL, Gaumont Y, Sirotnak
FM. Syntheses and antifolate activity of 5-methyl-5-deaza analogs of
aminopterin, methotrexate, folic acid and N10-methylfolic acid. J Med Chem
1986; 29: 1080-1087.
55. Rosowsky A, Chen KKN. Methotrexate analogs. 4. 7-Methyl derivatives of
methotrexate and dichloromethotrexate. New synthesis and some biological
studies. J Med Chem 1974; 17: 1308-1311.
56. McGuire JJ, Bolanowska WE, Coward JK, Sherwood RF, Russell CA,
Felschow DM. Biochemical and biological properties of methotrexate analogs
containing D-glutamic acid or D-erythro, threo-4-fluoroglutamic acid.
Biochem Pharmacol 1991; 42: 2400-2403.
356
57. Roth B, Aig E. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8.
The 3,4,5-triethyl isostere of trimethoprim. A study of specificity. J Med
Chem 1987; 30: 1998-2004.
58. El-Hamamsy MHRI, Smith AW, Thompson AS, Threadgill MD. Structure-
based design, synthesis and preliminary evaluation of selective inhibitors of
dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg Med Chem
2007; 15: 4552-4576.
59. Otzen T, Wempe EG, Kunz B, Bartels R, Yvetot GL, Hansel W et al. Folate-
synthesizing enzyme system as target for development of inhibitors and
inhibitor combinations against Candida albicans- synthesis and biological
activity of new 2,4-diaminopyrimidines and 4'-substituted 4-aminodiphenyl
sulfones. J Med Chem 2004; 47: 240-253.
60. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as
antibacterial agents. Biochem Pharmacol 2006; 71: 941-948.
61. Huang YL, Lin CF, Lee YJ, Li WW, Chao TC, Valeriy AB et al. Non-
classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines
and 2,4-diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies.
Bioorg Med Chem 2003; 11: 145-157.
62. Richardson ML, Croughton KA, Matthews CS, Stevens MFG. Structural
studies on bioactive compounds. 39. Biological consequences of the structural
modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-
3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims'). J Med Chem 2004; 47:
4105-4108.
63. Stevens MFG, Phillip KS, Rathbone DL, O'Shea DM, Queener SF, Schwalbe
CH et al. Structural studies on bioactive compounds. 28. Selective activity of
357
triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii
dihydrofolate reductase. J Med Chem 1997; 40: 1886-1893.
64. Robson C, Meek MA, Grunwaldt JD, Lambert PA, Queener SF, Schmidt D et
al. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: Activity as
inhibitors of dihydrofolate reductase from Pneumocystis carinii and
Toxoplasma gondii and as antitumor agents. J Med Chem 1997; 40: 3040-
3048.
65. Chan DCM, Laughton CA, Queener SF, Stevens MFG. Structural studies on
bioactive compounds. 34. Design, synthesis, and biological evaluation of
triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii
dihydrofolate reductase. J Med Chem 2001; 44: 2555-2564.
66. Richter WE, McCormack JJ. Inhibition of mammalian dihydrofolate reductase
by selected 2,4-diaminoquinazolines and related compounds. J Med Chem
1974; 17: 943-947.
67. Rogan PK, William GJB. The structure of the dihydrofolate reductase
inhibitor 2,4,6-triamino-5-chloroquinazoline. Acta Cryst Sect B 1980; 36:
2358-2362.
68. Rosowsky A, Mota CE, Wright JE, Queener SF. 2,4-Diamino-5-
chloroquinazoline analogs of trimetrexate and piritrexim: Synthesis and
antifolate activity. J Med Chem 1994; 37: 4522-4528.
69. Rosowsky A, Mota CE, Queener SF, Waltham M, Abali EE, Bertino JR. 2,4-
Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate
reductase with a site-directed mutation at position 22 and of the dihydrofolate
reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem
1995; 38: 745-752.
358
70. Gangjee A, Vidwans AP, Vasudevan A, Queener SF, Kisliuk RL, Cody V et
al. Structure-based design and synthesis of lipophilic 2,4-diamino-6-
substituted quinazolines and their evaluation as inhibitors of dihydrofolate
reductases and potential antitumor agents. J Med Chem 1998; 41: 3426-3434.
71. Thurmond J, Butchbach MER, Palomo M, Pease B, Rao M, Bedell L et al.
Synthesis and biological evaluation of novel 2,4-diaminoquinazoline
derivatives as SMN2 promoter activators for the potential treatment of spinal
muscular atrophy. J Med Chem 2008; 51: 449-469.
72. Gangjee A, Yu J, Kisliuk RL, Haile WH, Sobrero G, McGuire JJ. Design,
synthesis, and biological activities of classical N-{4-[2-(2-amino-4-ethyl
pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid and its 6-methyl
derivative as potential dual inhibitors of thymidylate synthase and
dihydrofolate reductase and as potential antitumor agents. J Med Chem 2003;
46: 591-600.
73. Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of a
classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-
oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg Med Chem
2006; 14: 8590-8598.
74. Gangjee A, Yu J, McGuire JJ, Cody V, Galitsky N, Kisliuk RL et al. Design,
synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate
synthase and dihydrofolate reductase as an antitumor agent. J Med Chem
2000; 43: 3837-3851.
75. Gangjee A, Vidwans A, Elzein E, McGuire JJ. Synthesis, antifolate and
antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-
pyrrolo[2,3-d]pyrimidines. J Med Chem 2001; 44: 1993-2003.
359
76. Gangjee A, Lin X, Queener SF. Design, synthesis and biological evaluation of
2,4- diamino -5-methyl -6- substituted pyrrolo [2,3-d] pyrimidines as
dihydrofolate reductase inhibitors. J Med Chem 2004; 47: 3689-3692.
77. Gangjee A, Lin X, Kisliuk RL, McGuire JJ. Synthesis of N-{4-[(2,4-diamino-
5-methyl-4,7-dihydro-3H- pyrrolo [2,3-d] pyrimidin-6-yl) thio] benzoyl}-L-
glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo
[2,3-d] pyrimidin-6-yl) thio] benzoyl}-L-glutamic acid as dual inhibitors of
dihydrofolate reductase and thymidylate synthase and as potential antitumor
agents. J Med Chem 2005; 48: 7215-7222.
78. Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of a
classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-
oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg Med Chem
2006; 14: 8590-8598.
79. Gangjee A, Li W, Yang J, Kisliuk RL. Design, synthesis, and biological
evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methyl
pyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate
reductase inhibitors. J Med Chem 2008; 51: 68-76.
80. Gangjee A, Adair O, Queener SF. Synthesis of 2,4-diamino-6-(thioarylmethyl)
pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Bioorg Med
Chem 2001; 9: 2929-2935.
81. Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Synthesis of classical and
nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates. J Med
Chem 2002; 45: 5173-5181.
82. Gangjee A, Adair O, Queener SF. Pneumocystis carinii and Toxoplasma
gondii dihydrofolate reductase inhibitors and antitumor agents: Synthesis and
360
biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)
methyl]-pyrido [2,3-d]pyrimidines. J Med Chem 1999; 42: 2447-2455.
83. Vilaivan T, Saesaengseerung N, Jarprung D, Kamchonwongpaisan S,
Sirawaraporn W, Yuthavong Y. Synthesis of solution phase combinatorial
library of 4,6-diamino-1,2-dihydro-1,3,5-triazine and identification of new
leads against A16v+S108T mutant dihydrofolate reductase of Plasmodium
falciparum. Bioorg Med Chem 2003; 11: 217-224.
84. Khlebnikov AI. The method of frontal polyhedra for conformationally
nonrigid molecules. Quantitative structure-activity relationship in the series of
baker triazines-dihydrofolate reductase inhibitors. Pharm Chem J 1997; 31:
147-154.
85. Maeda S, Kita T, Meguro K. Synthesis of novel 4,6-di(substituted)amino-1,2-
dihydro-1,3,5-triazine derivatives as topical antiseptic agents. J Med Chem
2009; 52: 597-600.
86. Baker BR, Ashton WT. Irreversible enzyme inhibitors. CLXXVI. Active site-
directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-
diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine by ether bridging to a
terminal sulfonyl fluoride. J Med Chem 1970; 13: 1149-1154.
87. Kim KH, Dietrich SW, Hansch C, Dolnick BJ, Bertino JR. Inhibition of
dihydrofolate reductase. 3. 4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-
substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor
enzymes. J Med Chem 1980; 23: 1248-1251.
88. Hansch C, Dietrich SW, Fukunaga JY. Inhibition of bovine and rat liver
dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4-
substituted phenyl)-s-triazines. J Med Chem 1981; 24: 544-549.
361
89. Booth RG, Selassie CD, Hansch C, Santi DV. Quantitative structure-activity
relationship of triazine-antifolate inhibition of leishmania dihydrofolate
reductase and cell growth. J Med Chem 1987; 30: 1218-1224.
90. Leroy D, Kajava AV, Frei C, Gasser SM. Analysis of Etoposide binding to
subdomains of human DNA topoisomerase IIα in the absence of DNA.
Biochemistry 2001; 40: 1624-1634.
91. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT et al.
Glide: A new approach for rapid, accurate docking and scoring. 1. Method
and assessment of docking accuracy. J Med Chem 2004; 47: 1739-1749.
92. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT et al.
Glide: A new approach for rapid, accurate docking and scoring. 2.
Enrichment factors in database screening. J Med Chem 2004; 47: 1750-1759.
93. Krovat EM, Steindl T, Langer T. Recent advances in docking and scoring.
Current Computer Aided Drug Design 2005; 1: 93-102.
94. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev
1971; 71: 525-616.
95. Wilkinson, Andrew M.; McNaught, Alan D. (1997). "Partition Coefficient".
Compendium of Chemical Terminology: IUPAC Recommendations. Oxford:
Blackwell Science.
96. Sangster J. (1997). Octanol-Water Partition Coefficients: Fundamentals and
Physical Chemistry, John Wiley & Sons Ltd. 1997; 2: 178.
97. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A.
Correlation of human jejunal permeability (in vivo) of drugs with
experimentally and theoretically derived parameters. A multivariate data
analysis approach. J Med Chem 1998; 41: 4939-4949.
362
98. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational
approach to predict blood-brain barrier permeability. Drug Metab Dispos
2004; 32: 132-139.
99. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1.
Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91:
129-156.
100. Kerns EH. High throughput physicochemical profiling for drug discovery. J
Pharm Sci 2001; 90: 1838-1858.
101. Mosmann T. Rapid colorimetric assay for cellular growth and survival:
Application to proliferation and cytotoxicity assays. J Immunol Meth 1983;
65: 55-63.
102. Cancer Cell Culture-method and protocols. Edited by Simon, P. Iandox.2004,
Humana press Inc, 999. Review Drive, Suit 208. Totowa, New Jersey.
103. Peterson LR, Collins SM. Bactericidal testing for infectious disease therapy:
The why and how to measure if we kill the bugs. Clin Microbiol Newsl 2000;
22: 153-157.
104. Venugopal D, Kumar S, Isa M, Bose M. Drug resistance profile of human
Mycobacterium avium complex strains from india. Ind J Med Microbiol 2007;
25: 115-120.
105. Cleidson V, Machado de SS, Elza FAS, Artur S Jr. Screening methods to
determine antibacterial activity of natural products. Braz J Microbiol 2007; 38:
369-380.
106. Brunton LL. In Goodman’s The Pharmacological Basis of Therapeutics’.
Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Goodman AG. Eds.,
10th ed.; McGraw-Hill: New York, 2001; 1006-1019.
363
107. Roberts S, McDonald IM. In Burger’s Medicinal Chemistry and Drug
Discovery, 6th ed.; Abraham DJ. Ed.; John Wiley: New Jersey, 2003; Vol 4:
86-121.
108. David Son’s Principle and Practice of Medicine, Upper gastrointestinal
disorders, 20th ed : Edinburgh ; New York : Churchill Livingstone, 2006; 863.
109. Herling AW, Weidmann K. In Burger’s Medicinal Chemistry and Drug
Discovery, 5th ed.; Wolff, ME. Ed.; John Wiley: New Jersey, 1996; Vol 2:
122-134.
110. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition
and antagonism of histamine H2-receptors. Nature 1972; 236: 385.
111. Durant GJ, Emmett JC, Ganellin CR. Smith Kline and French Laboratories
Limited. Pharmacologically active guanidine compounds. US Patent
3,950,333. 1976 Apr 13.
112. Price BJ, Clitherow JW, Bradshaw J. Allen and Hanburys Limited.
Aminoalkyl furan derivatives. US Patent 4,128,658. 1978 Dec 5.
113. Kromer W, Positus S, Kruger U. In Pharamceuticals; McGurie JL, Ed.; Wiley-
VCH: Weinhim, 2000; Vol 2:724.
114. Pfeiffer A, Kromer W, Friemann J, Ruge M, Herawi M, Schatzl M et al.
Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease.
Gut 1995; 36: 813-818.
115. Dammann HG, Burkhardt F. Influence of pantoprazole 40 MG and
omeprazole 20 MG on meal-stimulated gastric acid secretion.
Gastroenterology 1998; 114: A98.
116. Lazzaroni M, Sangaletti O, Parente F, Imbimbo BP, Porro BG. Inhibition of
food stimulated acid secretion by association of pirenzepine and ranitidine in
364
duodenal ulcer patients. Int J Clin Pharmacol Ther Toxicol 1986; 24: 685-688.
117. Wyllie JH, Hesselbo T, Black JW. Effects in man of histamine H2-receptor
blockade by burimamide. The Lancet 1972; 300: 1117-1120.
118. Duncan WAM, Parsons ME. Reminiscences of the development of cimetidine.
Gastroenterology 1980; 78: 620-625.
119. Hirata Y, Yanagisawa I, Ishii Y, Tsukamoto S, Ito N, Isomura Y et al.
Yamanouchi Pharmaceutical Co Limited. Guanidino thiazole compounds,
process for the preparation and gastric inhibiting compositions containing
them. US Patent 4,283,408. 1981 Aug 11.
120. Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with
cimetidine and ranitidine. Clin Pharm 1988; 7: 271-284.
121. Pioch RP. EP 49,618, 1985.
122. Shibata K, Etaya T, Yamakoshi N, Kurata S, Koizumi N, Tarutani M et al. EP
24,510 B1 1983.
123. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-
receptor antagonists. Relationship between intrinsic potency and effective
plasma concentrations. Clin Pharmacokinet 1991; 20: 218-236.
124. Scheuch E, Walter R, Hadasova E, Amon HI, Siegmund W. Influence of H2-
receptor and proton pump inhibitors on some functions of the oxidative and
conjugative drug metabolism. Pharmazie 1996; 51: 493-497.
125. Brittain RT, Daly MJ. A review of the animal pharmacology of ranitidine a
new, selective histamine H2-antagonist. Scand J Gastroenterol Suppl 1981; 69:
1-9.
126. Labenz J. Consequences of Helicobacter pylori cure in ulcer patients.
Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 133-145.
365
127. McCarthy DM. Sucralfate. N Engl J Med 1991; 325: 1017-1025.
128. Collins PW. Misoprostol: Discovery, development, and clinical applications.
Med Res Rev 1990; 10: 149-172.
129. Okamoto CT, Forte JG. Vesicular trafficking machinery, the actin
cytoskeleton, and H+/K+-ATPase recycling in the gastric parietal cell. J
Physiol 2001; 532: 287-296.
130. Ruwart MJ, Nezamis JE, Rush BD, Lancaster C, Davis JP, Nichols NM et al.
Timoprazole is a unique cytoprotective agent in the rat. Digestion 1984; 30:
33-40.
131. Lindberg P, Brandstrom A, Wallmark B, Mattsson H, Rikner L, Hoffmann KJ.
Omeprazole: The first proton pump inhibitor. Med Res Rev 1990; 10: 1-54.
132. Yamada M, Yura T, Morimoto M, Harada T, Yamada K, Honma Y et al.
2-[ (2-Aminobenzyl) sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent [d]
imidazoles as a novel class of gastric H+/K+-ATPase inhibitors. J Med Chem
1996; 39: 596-604.
133. Angela AMCC, Eibert RH, Eijk V, Jacques THM, Cornelis BHWL, Hubert
GML. Determinants of headache in lansoprazole users in the netherlands:
Results from a nested case-control study. Drug Saf 2002; 25: 287-295.
134. Robinson M. Current perspectives on hyper gastrinaemia and
enterochromaffin like cell hyperplasia. Aliment Pharmacol Ther 1999; 13: 5-
10.
135. Ife RJ, Dyke CA, Keeling DJ, Meenan E, Meeson ML, Parson ME et al. 2-[[
(4-Amino-2-pyridyl) methyl] sulfinyl] benzimidazole H+/K+-ATPase
inhibitors. The relationship between pyridine basicity, stability, and activity. J
Med Chem 1989; 32: 1970-1977.
366
136. Weidmann K, Herling AW, Lang HJ, Scheunemann KH, Rippel R,
Nimmesgern H et al. 2-[(2-Pyridylmethyl) sulfinyl]-1H-thieno [3,4-d]
imidazoles. A novel class of gastric H+/K+-ATPase inhibitors. J Med Chem
1992; 35: 438-450.
137. Munson K, Garcia R, Sachs G. Inhibitor and ion binding sites on the gastric
H+/K+-ATPase. Biochemistry 2005; 44: 5267-5284.
138. Suschitzky JL, Wells E. In Comprehensive Medicinal Chemistry; Hansch C.
Ed.; Oxford, Pergamon Press: 2005; 2: 197-202.
139. Lindberg P, Nordberg P, Alminger T, Braendstroem A, Wallmark B. The
mechanism of action of the antisecretory agent omeprazole. J Med Chem
1986; 29: 1327-1329.
140. Esomeprazole. Med Lett Drugs Ther 2001; 43: 36-37.
141. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors
and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4: 597-604.
142. Gisbert JP, Pajares JM, Losa C. Helicobacter pylori and gastroesophageal
reflux disease: Friends or foes. Hepato gastroenterology 1999; 46: 1023-1029.
143. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection
accelerates healing of reflux esophagitis during treatment with the proton
pump inhibitor pantoprazole. Gasteroenterology 1999; 117: 11-16.
144. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of
the gastric acid pump: The H+/K+-ATPase. Annu Rev Pharmacol Toxicol
1995; 35: 277-305.
145. Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid
suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther
2000; 14: 963-978.
367
146. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral
pharmacokinetics of omeprazole and lansoprazole after single and repeated
doses as intact capsules or as suspensions in sodium bicarbonate. Aliment
Pharmacol Ther 2000; 14: 887-892.
147. Monthly Index of Medical Specialties. Duncan C. Ed.;Hay London, Market
Publishing Services: 2002.
148. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W et al.
Beyond gastric acid reduction: Proton pump inhibitors induce heme
oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun
2006; 345: 1014-1021.
149. Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging
reactivity of proton pump inhibitors. Biochem Pharmacol 2006; 71: 1337-
1341.
150. Katagiri F, Inoue S, Sato Y, Itoh H, Takeyama M. Comparison of the effects
of proton pump inhibitors on human plasma adrenocorticotropic hormone
and cortisol levels under the starved condition. Biomed Pharamacother 2006;
60: 109-112.
151. Tsukimi Y, Ushiro T, Yamazaki T, Ishikawa H, Hirase J, Narita M et al.
Studies on the mechanism of action of the gastric H+/K+-ATPase inhibitor
SPI-447. Jpn J Pharmacol 2000; 82: 21-28.
152. Keeling DJ, Laing SM, Bilfinger JS. SCH 28080 is a lumenally acting, K+-site
inhibitor of the gastric H+/K+-ATPase. Biochem Pharmacol 1988; 37: 2231-
2236.
153. Wallmark B, Briving C, Fryklund J, Munson K, Jackson R, Mendlein J et al.
Inhibition of gastric H+\K
+-ATPase and acid secretion by SCH 28080, a
368
substituted pyridyl(1,2a)imidazole. J Biol Chem 1987; 262: 2077-2084.
154. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y.
The long-lasting effect of TU-199, a novel H+\K
+-ATPase inhibitor, on gastric
acid secretion in dogs. J Pharm Pharmacol 1999; 51: 457-464.
155. Sachs G, Chang HH, Rabon E, Shackman R, Lewin M, Saccomani G. A
nonelectrogenic H+ pump in plasma membranes of dog stomach. J Biol Chem
1976; 251: 7690-.7698
156. Clissold SP, Campoli Richards DM. Omeprazole. A preliminary review of its
pharmacodynamic and pharmacokinetic properties, and therapeutic potential in
peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.
157. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and
toxicology of omeprazole with special reference to the effects on the gastric
mucosa. Scand J Gastroenterol 1986; 21(Suppl. 118): 31-38.
158. Hakanson R, Sunder F. Gastric carcinoids and antisecretory drugs. Trends
Pharmacol Sci 1986; 7: 386-387.
159. Pope AJ, Parsons ME. Reversible inhibitors of the gastric H+/K+-transporting
ATPase: A new class of anti-secretory agent. Trends Pharmacol Sci 1993; 14:
323-325.
160. LaMattina JL, McCarthy PA, Reiter LA, Holt WF, Yeh LA. Antiulcer agents.
4-Substituted 2-guanidinothiazoles: Reversible, competitive and selective
inhibitors of gastric H+/K+-ATPase. J Med Chem 1990; 33: 543-552.
161. Woo TW, Chang MS, Chung YK, Kim KB, Sohn SK, Kim SG et al. Effects of
YJA20379-4 on gastric secretion, helicobacter pylori growth and various
gastric and duodenal lesions in rats. Biol Pharm Bull 1998; 21: 449-455.
369
162. Kim KB, Park SH, Lee JM, Choi WS, Paek JH, Seo KH et al. WO 9703077,
1997.
163. Yoon SH, Seo S, Lee YH, Hwang SK, Kim DY. Syntheses of 2-[(3,5-
dimethyl-4-methoxypyridyl)alkyl]-benzothiazolidine derivatives as a potential
gastric H+/K+-ATPase inhibitor. Bioorg Med Chem Lett 1998; 8: 1909-1912.
164. Sih JC, Im WB, Robert A, Graber DR, Blakeman DP. Studies on (H+-K+)-
ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinyl
methyl) sulfinyl] benzimidazole proton-pump inhibitors. J Med Chem 1991;
34: 1049-1062.
165. Nelson KS, Krasso A, Muller RM, Fischli AE. Ro 18-5364, a potent new
inhibitor of the gastric H+\K
+-ATPase. Eur J Biochem 1987; 166: 453-459.
166. Yoo HY, Chung KJ, Chai JP, Chang MS, Kim SG, Choi WS, Kim YH, Chun
JK, Chung YK, Kim YH, Paek JH, Seo KH, Kang DP. EP 843681, 2002.
167. Shin JM, Sachs G, Cho Y, Garst M. 1-Arylsulfonyl-2-(pyridylmethylsulfinyl)
benzimidazoles as new proton pump inhibitor prodrugs. Molecules 2009; 14:
5247-5280.
168. Uchida M, Chihiro M, Morita S, Yamashita H, Yamasaki K, Kanbe T et al.
Synthesis and antiulcer activity of 4-substituted 8-[(2-benzimidazolyl)
sulfinylmethyl]-1,2,3,4-tetra-hydroquinolines and related compounds. Chem
Pharm Bull 1990; 38: 1575-1586.
169. Yamada S, Goto T, Yamaguchi T, Aihara K, Kogi K, Narita S. Synthetic
study of 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-sulfinyl]-1H-
benzimidazole analogs and their biological properties as novel proton pump
inhibitors. Chem Pharm Bull 1995; 43: 421-431.
370
170. Terashima K, Sato M, Ono M, Muraoka O. Synthesis and mechanism of
action of ethyl-2-[(1H benzimidazol-2-yl)sulfinylmethyl]-4-dimethyl amino-5-
pyridine carboxylate, a New H+/K+-ATPase inhibitor associated with
Mucosal Protective Activity, AFMC, Medicinal Chemistry Symposium, 1995.
171. Tsukahara T, Takahashi S, Okabe S. Gasteroenterology 1996; 110: A281.
172. Weidmann K, Herling AW, Lang HJ, Scheunemann KH, Rippel R,
Nimmesgern H et al. 2-[(2-Pyridylmethyl)sulfinyl]-1H-thieno[3,4-
d]imidazoles. A novel class of gastric H+\K
+-ATPase. J Med Chem 1992; 35:
438-450.
173. Terauchi H, Tanitame A, Tada K, Nakamura K, Seto Y, Nishikawa Y.
Nicotinamide derivatives as a new class of gastric H+/K+-ATPase inhibitors.
1. Synthesis and structure-activity relationships of N-substituted 2-
(benzhydryl and benzylsulfinyl) nicotinamides. J Med Chem 1997; 40: 313-
321.
174. Berzsenyi P, Sebestyen L, Meresz MM, Andrasi F. GYKI 34 655: A potent
gastric antisecretory and antiulcer/cytoprotective drug. Pharmacol Res 1995;
31: 94.
175. Mora CC. Piperazines. US Patent 4,278,796. 1981 Jul 14.
176. Murai H, Ohata K, Aoyagi Y, Ueda F, Kitano M, Takata S et al. Nippon
Shinyaku Co Ltd. Benzoguanamine derivatives. US Patent 3,966,728. 1976
June 29.
177. Hirosada S, Watanable M, Mitsuru K, Isuke I. EP 0,00,3084, 1982.
178. Otsubo K, Morita S, Uchida M, Yamasaki K, Kanbe T, Shimizu T. Synthesis
and antiulcer activity of optical isomers of 2-(4-chlorobenzoylamino)-3-
[2(1H)-quinolinon-4-yl] propionic acid (Rebamipide). Chem Pharm Bull 1991;
371
39: 2906-2909.
179. Miki T, Asano M, Hosokami T. EP 0,185,368, 1990; Chem Abstr 1986; 105:
172063.
180. Hino K, Kawashima K, Oka M, Nagai Y, Uno H, Matsumoto J. A novel class
of antiulcer agents. 4-Phenyl-2-(1-piperazinyl)quinolines. Chem Pharm Bull
1989; 37: 110-115.
181. Katano K, Tomomoto T, Ogino H, Yamazaki N, Hirano F, Yuda Y. EP
0,405,976, 1995; Chem Abstr 1991; 114: 228904.
182. OECD 2001-guideline on acute oral toxicity (AOT) Environmental health and
safety monograph series on testing and adjustment No.425.
183. Paget GE, Barnes JM. “Evaluation Drug Activities and Pharmacokinetics”,
Laurance DR, Bachrach AC. New York: Academic Press 1983 Vol-1.
184. Vogel GH, Vogel WH. Drug discovery and evaluation of pharmacological
assays, 2nd ed, Germany, Springer vealag Berlin Heeidelberg, 1997; 486-490.
185. Kulakarni SK. Hand book of exp Kulkarni SK. Hand book of experimental
pharmacology, 3rd ed, Punjab University Chandigarh, Vallabh Prakashan 148-
150.
186. Shay H, Komarov SA, Fels SS, Meeranze D, Gruenstein M, Siplet H. A
simple method for the uniform production of gastric ulceration.
Gastroenterology 1945; 5: 43-61.
187. Hawk PB, Oser B, Summerson WH. Practical Physiological Chemistry (12th
ed.) 1947; 579- 589. The Blakiston Co., Philadelphia.
188. Thangam C, Dhananjayam R. Antiinflammatory potential of the seeds of
Carum Copticum Linn. Indian J Pharmacol 2003; 38: 388.
372
189. Cotran RS, Kurma V, Collins T, Robbins. Pathological basis of disease 6th ed.,
New York; W.B Saunder’s Company, 2001.
190. Kavimani S, Vetrichalvan T, Nagarajan NS. Indian Drugs 2002; 99: 161.
191. Banerjee S, Kumar ST, Mandal S, Chandra DP, Sikdar S. Assessment of the
anti-inflammatory effects of Swertia chirata in acute and chronic experimental
models in male albino rats. Indian J Pharmacol 2000; 32: 21.
Recommended